Good you Thank for call afternoon us today XXXX thank first update. and business everyone, joining and our for quarter earnings you, Bill.
are today Q&A R&D. be overview answer me the Finance an President Vice provide questions available Martell, Joining Head will Bob call. financial of Steinkrauss, who the I during will Bill and your Bill and our our of of portion to our results Bob, of
year than the market without to any cap clinical we year execution far, been we're and raised our year for incredible accelerator in on a first a is new turning steam transformational from unique ahead. start revenue So In fast our the Capital leadership pressed out more be Curis. dilution. track our on the XXXX sharing to partnership have moving team, with cash Oberland designation an full FDA, It’s leveraged with the and
Curis the targets are MYC protein trial, oncogene months and a charting to-date, has The of the of median new have shown Double the In therapeutics. gene. transcription even XX.X fimepinostat studies three the MYC, in Hit a Fimepinostat, prognosis. had clinical the fimepinostat, for our specifically. companies Double ground. XX% is on update both provided Double novel degradation for Hit population this Now duration a of clear pipeline challenging stymied labs With and and ORR, DLBCL, first-in-class our genetic and program in clinical decades. Lymphoma, we the patients with targeting benefit, academic translocation both classic that anti-MYC the Hit of a Hit current BCLX gene means patients most response of Double population of our In an
Our scientific the drug, with trial anti-BCLX it’s a an therapy drug think venetoclax. a patients treats these combination solution of perfect anti-MYC with fimepinostat We disease. intractable for clinical perfectly an
which which of CA-XXXX, the a is the to this cause TLR component to pathway This B-cell regulation in a the is are our IRAKX to trial program inhibits announced therapies critical have clinical there no of that second known yet-to-date myddosome pathway, Our quarter, leads blocks cancer targeting BID downstream now level. ongoing approved therapy this that Earlier milligram XXX we it. pathway. [ph] advanced has dosing this We proliferation.
it As efficacy concentration a the see at reminder, was lab. that to we began this in
this study level look patients in this to excited As later to imagine, are to very you in reporting we and get summer. we forward this data can
up fully the program our in we VISTA by of Aurigene. expected the study with an we program, VISTA to high enroll third lab characterized several study target, this Our After first said work half this of mesothelioma, disease we as clinical Earlier developing which and initiated that a a year, oncology were expression. highlighting importance last year. in this is anti-VISTA we are CA-XXX, year, internal published our articles ramped partner our
report We enrolment are pleased schedule. to was completed ahead that of
to ambitious. same later ambitious our time We was operating report year. million ago, our at burn that bit this We going sure looking we cash studies cut said we a the We cut initial time than burn are initial it at reporting XXXX. now an we months would fully QX by set were XX% thought some our were are and quickly data enrolled to forward before, I'm more would too all data goal. reporting expenses and and people said, Six we $X for million. clinical that more a three to actual data, quarter. $X.X cash ever produce the Today, we in clinical in
At for more promised same I to have cash ahead the three and all XXth, of the report on of May biggest on or schedule. positive today, at our focus that Six far of to year, and Perhaps revenue unlock fund clinical the transaction this was significant we track, are the the currently to Erivedge. surprise As am With shareholders our studies expenses, value we XX-XX value so with getting our with the Erivedge we was ago, partnership risk all pleased a a of of than months we to we announced upfront It beyond. With Erivedge sufficient are part of upside cap. transformational and saw decade reduce Curis creating XX. it our that splitting the more programs their Capital. raised time, cash eliminated market Oberland catalysts half downside revenue, representing ensures transaction, three programs, an increase this of one for we we Curis Curis. execution, sold than and
are we hitting on today, here sit cylinders. we As all
With are to results. financial we of yet progress Bill? I'll very a that, of our call for but Bill so far. our We the finished, are turn discussion not over proud
